Poseida Therapeutics, Inc. Stock price

Equities

PSTX

US73730P1084

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.19 USD +3.57% Intraday chart for Poseida Therapeutics, Inc. +4.93% -5.06%
Sales 2024 * 46.67M Sales 2025 * 21.25M Capitalization 308M
Net income 2024 * -184M Net income 2025 * -230M EV / Sales 2024 * 6.6 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 14.5 x
P/E ratio 2024 *
-1.85 x
P/E ratio 2025 *
-1.76 x
Employees 330
Yield 2024 *
-
Yield 2025 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Poseida Therapeutics Appoints Syed Rizvi as Chief Medical Officer MT
Poseida Therapeutics, Inc Appoints Syed Rizvi as Chief Medical Officer Effective April 1, 2024 CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M MT
Poseida Therapeutics, Inc. Announces Executive Changes CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Poseida Therapeutics, Inc.(NasdaqGS:PSTX) dropped from NASDAQ Biotechnology Index CI
Piper Sandler Adjusts Price Target on Poseida Therapeutics to $10 From $8, Maintains Overweight Rating MT
Poseida Therapeutics Reports Positive Results of Phase 1 Blood Cancer Treatment Trial MT
Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment DJ
HC Wainwright Adjusts Price Target on Poseida Therapeutics to $20 From $15, Keeps Buy Rating MT
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Poseida Therapeutics, Inc. Announces Board Changes CI
More news
1 day+3.57%
1 week+4.93%
Current month-19.44%
1 month-14.25%
3 months-8.33%
6 months+30.20%
Current year-5.06%
More quotes
1 week
2.81
Extreme 2.81
3.24
1 month
2.80
Extreme 2.8
4.27
Current year
2.65
Extreme 2.65
4.27
1 year
1.54
Extreme 1.54
4.27
3 years
1.54
Extreme 1.54
11.10
5 years
1.54
Extreme 1.54
17.62
10 years
1.54
Extreme 1.54
17.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 23-03-31
Director of Finance/CFO 37 15-05-31
Chairman 61 18-01-31
Members of the board TitleAgeSince
Director/Board Member 75 18-12-31
Director/Board Member 65 21-07-22
Chairman 61 18-01-31
More insiders
Date Price Change Volume
24-03-28 3.19 +3.57% 698,380
24-03-27 3.08 +9.61% 671,288
24-03-26 2.81 -7.57% 625,660
24-03-25 3.04 -2.25% 563,132
24-03-22 3.11 +2.30% 498,386

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's approach to cell and gene therapies is based on its genetic editing platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies. Its P-MUC1C-ALLO1 is an allogeneic CAR-T product candidate with the potential to treat a range of solid tumor indications, including breast and other epithelial-derived cancers. Its product candidate, P-PSMA- ALLO1, is being developed for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). Its product candidate P-BCMA-ALLO1 and P-BCMACD19-ALLO1 is developed for patients with multiple myeloma. Its P-CD19CD20-ALLO1 is an allogeneic, CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.19 USD
Average target price
14 USD
Spread / Average Target
+338.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Poseida Therapeutics, Inc. - Nasdaq